Eli Lilly Bets $2.75 Billion on Insilico's AI Drug Pipeline

A major pharmaceutical alliance is putting a significant valuation on artificial intelligence in drug discovery. Eli Lilly has entered a partnership potentially worth $2.75 billion with Hong Kong-based Insilico Medicine, aiming to commercialize medicines designed using Insilico's generative AI platforms.

The deal provides Insilico with an upfront payment of $115 million. The substantial remainder of the figure is contingent on the achievement of future development, regulatory, and sales targets, plus royalties. Insilico, which became a public company in Hong Kong late last year, reports its AI systems have produced 28 drug candidates, with close to half already in clinical trials.

This agreement expands a relationship that began with a software licensing deal in 2023. Insilico will now join Lilly's Gateway Labs, a collaborative biotech development community. Alex Zhavoronkov, Insilico's founder and CEO, noted the complementary strengths, stating Lilly has deep expertise in integrating biology, chemistry, and automation. 'In many ways, Lilly is better than us in some areas of AI,' he told CNBC.

For Lilly, the move represents a strategic acceleration of its discovery efforts. 'This collaboration allows us to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas,' said Andrew Adams, Lilly's group vice president of Molecule Discovery. He described Insilico's technology as a powerful addition to the company's clinical development engine.

The partnership emerges as Lilly increases its engagement in the region. CEO David Ricks recently attended a forum in Beijing, following the company's announcement of a planned $3 billion investment in China over the next ten years. Insilico conducts its core AI research outside of China, in Canada and the Middle East, but performs early-stage preclinical work in China based on those AI models, a structure Zhavoronkov says can synthesize candidate molecules far faster than conventional methods.

Source: CNBC